What is Iovance Biotherapeutics, Inc.'s Shariah compliance score?

Iovance Biotherapeutics, Inc. (IOVA) has a Shariah compliance score of 92/100 (Grade: A+, Excellent) based on AAOIFI screening standards. Scores above 70 typically indicate strong compliance. The score factors in business activity screening and financial ratio analysis including debt levels, interest-bearing deposits, and prohibited income percentages. View the full breakdown at HalalScreener.app.

Does Iovance Biotherapeutics, Inc. pass AAOIFI screening?

Iovance Biotherapeutics, Inc. (IOVA) passes AAOIFI Shariah screening. AAOIFI requires: (1) no primary involvement in prohibited activities like alcohol, gambling, or conventional banking, (2) debt-to-market-cap below 30% (IOVA: 1.3%), (3) interest-bearing deposits below 30%, and (4) prohibited income below 5%. HalalScreener provides free AAOIFI screening for 6,200+ stocks at halalscreener.app.

How much purification is needed for Iovance Biotherapeutics, Inc. stock?

Muslim investors purify the portion of dividends and realized gains that comes from non-permissible income by donating it to charity. HalalScreener's purification calculator at halalscreener.app/en/purification computes the exact percentage and amount for Iovance Biotherapeutics, Inc. (IOVA) using the latest financial data.

Where can I screen Iovance Biotherapeutics, Inc. for Shariah compliance for free?

HalalScreener (halalscreener.app) offers free Shariah compliance screening for Iovance Biotherapeutics, Inc. (IOVA) and 5,100+ other US-listed stocks, ETFs, and 100+ cryptocurrencies. The screening uses AAOIFI Standard No. 21 and shows the verdict, compliance grade, score, and debt ratio free. No credit card or signup required for basic screening; the full ratio breakdown is part of Pro. HalalScreener also includes an AI Islamic Scholar for follow-up questions about IOVA's compliance across different madhabs (Hanafi, Shafi'i, Maliki, Hanbali, Ja'fari).

IOVA: Is Iovance Biotherapeutics, Inc. Halal?

Iovance Biotherapeutics, Inc.

NASDAQHealthcareUS

$3.93

+2.88%

Market Cap: 1.4B

Compliance Status

Halal

Screened on Sep 1, 2026 · AAOIFI Standard 21

A+

Excellent

92Score

Is Iovance Biotherapeutics, Inc. (IOVA) halal? Halal. Based on AAOIFI screening, Iovance Biotherapeutics, Inc. passes both qualitative (business activity) and quantitative (financial ratio) screens with a compliance score of 92/100 (Grade: A+).

Quote this verdict

HalalScreener rates Iovance Biotherapeutics, Inc. (IOVA) Halal, 92/100, grade A+ under AAOIFI Standard 21, screened Sep 1, 2026. Source: https://halalscreener.app/en/stock/IOVA

AvoidBorderlineClean

Business activity

What the company sells is permissible.

Passed

Company debt

Well clear of the limit

How much the company borrows, compared to its total value. AAOIFI allows up to 30%.

1.3% of 30.0% limit

What this means for you

You can own IOVA

It passes both the business activity and financial ratio screens under AAOIFI Standard 21.

Purification amount is Pro

We have screened IOVA's prohibited income, but the exact share you would need to purify is part of Pro.

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.

Sector: Healthcare · Industry: Biotechnology

Shariah Compliance Status

AAOIFI Standard 21Updated Sep 1, 2026

Compliance History

Halalnow
since Aug 2026
Not Halal
until the change above
Halal
until the change above

Tracked since Jun 2026. Updates automatically on each re-screen.

Fiscal: Q2 2026Data source: EDGAR

More Healthcare Stocks

JNJ

Johnson & Johnson

UNH

UnitedHealth Group Incorporated

ABBV

AbbVie Inc.

PFE

Pfizer Inc.

LLY

Eli Lilly and Company

A+

MRK

Merck & Co., Inc.

Free · No credit card required

Track IOVA and 6,200+ stocks with AI insights

Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.

Get Started Free Browse Screener

6,200+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is Iovance Biotherapeutics, Inc. (IOVA) halal to invest in?

Based on AAOIFI Standard 21 screening, Iovance Biotherapeutics, Inc. (IOVA) is rated Halal with a compliance grade of A+ (Excellent). It passes both the business activity screen (no primary involvement in prohibited sectors) and the quantitative financial ratio screen (debt, interest deposits, and prohibited income all below AAOIFI thresholds).

Why did Iovance Biotherapeutics, Inc. get a A+ compliance rating?

Iovance Biotherapeutics, Inc. (IOVA) received a grade of A+ (Excellent) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 1.3% (limit 30%). The grade reflects the margin of safety across all three ratios relative to their thresholds.

What could change Iovance Biotherapeutics, Inc.'s Shariah verdict?

Iovance Biotherapeutics, Inc.'s verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.

How often is Iovance Biotherapeutics, Inc. re-screened for Shariah compliance?

Iovance Biotherapeutics, Inc. (IOVA) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Sep 1, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.